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ABSTRACT
Rationale Mandibular advancement devices (MADs)
are used to treat obstructive sleep apnoea-hypopnoea
syndrome (OSAHS) but evidence is lacking regarding
their clinical and cost-effectiveness in less severe disease.
Objectives To compare clinical- and cost-effectiveness
of a range of MADs against no treatment in mild to
moderate OSAHS.
Measurements and methods This open-label,
randomised, controlled, crossover trial was undertaken at
a UK sleep centre. Adults with Apnoea-Hypopnoea Index
(AHI) 5–<30/h and Epworth Sleepiness Scale (ESS) score
≥9 underwent 6 weeks of treatment with three non-
adjustable MADs: self-moulded (SleepPro 1; SP1);
semi-bespoke (SleepPro 2; SP2); fully-bespoke MAD
(bMAD); and 4 weeks no treatment. Primary outcome
was AHI scored by a polysomnographer blinded to
treatment. Secondary outcomes included ESS, quality of
life, resource use and cost.
Main results 90 patients were randomised and 83
were analysed. All devices reduced AHI compared with
no treatment by 26% (95% CI 11% to 38%, p=0.001)
for SP1, 33% (95% CI 24% to 41%) for SP2 and 36%
(95% CI 24% to 45%, p<0.001) for bMAD. ESS was
1.51 (95% CI 0.73 to 2.29, p<0.001, SP1) to 2.37
(95% CI 1.53 to 3.22, p<0.001, bMAD) lower than no
treatment (p<0.001 for all). Compliance was lower for
SP1, which was the least preferred treatment at trial exit.
All devices were cost-effective compared with no
treatment at a £20 000/quality-adjusted life year (QALY)
threshold. SP2 was the most cost-effective up to
£39 800/QALY.
Conclusions Non-adjustable MADs achieve clinically
important improvements in mild to moderate OSAHS and
are cost-effective. Of those trialled, the semi-bespoke
MAD is an appropriate first choice.
Trial registration number ISRCTN02309506.
INTRODUCTION
Obstructive sleep apnoea-hypopnoea (OSAH)
involves repeated collapse of the pharyngeal airway
during sleep, causing oxygen desaturations and
brief arousals. OSAH syndrome (OSAHS) incorpo-
rates excessive daytime sleepiness (EDS),1 affecting
2%–7% of adults.2
There is a causal link with hypertension3 and car-
diovascular risk is increased 2.5-fold,4 with a
reported 6% increase in stroke risk per unit
increase in Apnoea-Hypopnoea Index (AHI/hour).5
Road traffic accident risk is two to three times
higher6 and health-related quality of life (HRQoL)
is impaired.7 Healthcare usage is almost doubled in
OSAHS, with the main determinants of increased
cost being cardiovascular disease and psychoactive
medication.8
Weight loss sometimes cures OSAHS but CPAP
therapy gives immediate control of obstructive
events. Improvement in EDS usually follows, with
added benefits to driving safety and HRQoL.9
Meta-analyses have shown that CPAP reduces mean
blood pressure by around 2 mm Hg10 and observa-
tional data have suggested cardiovascular risk
reduction.11
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Key messages
What is the key question?
▸ Are mandibular advancement devices (MADs)
clinically- and cost-effective compared with no
treatment in mild to moderate obstructive sleep
apnoea-hypopnoea syndrome (OSAHS), and
does the degree of MAD sophistication
influence outcomes?
What is the bottom line?
▸ Clinical and cost-effectiveness analyses suggest
that semi-bespoke non-adjustable devices
should be offered as first line treatment for
mild OSAHS and as an alternative to CPAP in
moderate disease, whereas dentally-fitted
bespoke devices should be reserved for those
who cannot produce the mould for, or tolerate,
a semi-bespoke device; and while adjustable
MADs offer some advantages, their precise role
and cost-effectiveness still need to be
established.
Why read on?
▸ This is the first comprehensive randomised
controlled trial to evaluate both the clinical and
cost-effectiveness of MADs for the treatment of
mild to moderate OSAHS; the results and their
implications for clinical practice are discussed.
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CPAP is recommended by the National Institute for Health
and Care Excellence as clinically and cost-effective for moderate
to severe OSAHS.12 Benefits are less certain in milder disease,
although there is some evidence of improvement in functional
outcomes and daytime sleepiness.13 14 Intolerance of CPAP is
common, affecting 46%–83% of patients across the disease
spectrum.15 Effective alternatives to CPAP are therefore needed.
Intraoral mandibular advancement devices (MADs) protrude
the mandible and tongue to maintain upper airway patency
during sleep. Meta-analyses suggest MADs are beneficial in
OSAHS, although trial and device heterogeneity complicate
interpretation.16 Most comparative studies show CPAP is better
at controlling respiratory events but both treatments improve
sleepiness equally, possibly due to CPAP intolerance.17 MADs
are effective compared with sham MADs in reducing AHI and
improving sleepiness. However, adverse sham effects may exag-
gerate treatment benefits of active devices by undermining sleep
quality without reducing respiratory events,16 although there is
evidence to the contrary in more severe OSAHS.18 Nonetheless,
it is important to compare the effectiveness of MADs with no
treatment in milder disease, where the balance of costs and ben-
efits may be more marginal.19 The considerable heterogeneity in
MAD treatment, caused by variation in device design, produc-
tion processes and specialist involvement, also results in cost
variability. There is therefore a need to explore the clinical and
cost-effectiveness of a range of MADs. This study aimed to
determine whether:
1. MADs are clinically- and cost-effective compared with no
treatment in mild to moderate OSAHS.
2. The degree of MAD sophistication influences outcomes,
including cost-effectiveness.
METHODS
Open-label, four-period, crossover, randomised controlled trial
(RCT) comparing three non-adjustable MADs with no
treatment.
Full details of trial methodology are included in an online
supplement.
Participants
Patients aged ≥18 years with mild to moderate OSAHS con-
firmed by respiratory polysomnography (rPSG) (AHI 5–<30/h)
and symptomatic daytime sleepiness (Epworth Sleepiness Scale
(ESS) score ≥9) were recruited from Papworth Hospital sleep
centre. Newly diagnosed patients not requiring or declining
CPAP and existing CPAP intolerant patients were eligible. See
online supplement for exclusion criteria.
Procedures
The three MADs were: thermoplastic ‘boil and bite’ device
(SleepPro 1 (SP1); Meditas, Winchester, UK); semi-bespoke
device produced from a patient-moulded dental impression kit
(SleepPro 2 (SP2); Meditas); bespoke MAD (bMAD) device
fitted and manufactured by National Health Service (NHS)
Maxillofacial Team at Addenbrooke’s Hospital, Cambridge, UK.
After dental eligibility was confirmed, patients were rando-
mised via telephone by the hospital’s R&D unit using Williams’
Latin Squares with allocations generated by computer, using per-
muted blocks of eight.
Period duration was 6 weeks (4 weeks for no treatment):
2 weeks acclimatisation and 4 weeks treatment. One week’s
washout followed active treatments. Outcomes were obtained at
baseline and at the end of each treatment period.
Outcomes
Primary outcome was AHI, measured by domiciliary rPSG
(Embletta, Embla Systems, Kanata, Ontario, Canada) and scored
by a polysomnographer blinded to treatment. Other outcomes
included rPSG indices, blood pressure, subjective sleepiness (ESS),
sleep-related quality of life (Functional Outcomes of Sleep
Questionnaire (FOSQ); Calgary Sleep Apnoea Quality of Life
Index (SAQLI)) and generic HRQoL (Short Form 36 (SF36);
EuroQol (EQ-5D-3L)). Healthcare usage, road traffic accidents
and treatment satisfaction were recorded at the end of each treat-
ment period. Treatment compliance was calculated at the end of
each treatment period from a patient-completed diary. Device
preference was documented at trial exit.
Statistical analysis
Calculations indicated 72 patients for 80% power to detect
treatment effects of 1/3 SDs between MADs (two-sided 5% sig-
nificance). A total of 90 patients were recruited, allowing 20%
loss to follow-up. All randomised patients were followed up and
available results from periods included in analysis irrespective of
treatment compliance (‘intention to treat’).
Mixed effects Poisson regression was used to estimate effects
of treatment, period and treatment by period interactions for
AHI. Mixed effects logistic regression was used to analyse
response (complete (AHI <5) or partial (AHI ≥5 with ≥50%
reduction from baseline)). All other outcomes were analysed
using linear mixed models.
Regressions explored the effects on AHI response of baseline
AHI, ESS, age, gender, compliance and body mass index (BMI),
and BMI changes over time.
Economic analysis
Using an NHS perspective, device costs, fitting time and other
healthcare usage within each treatment period were compared
against the costs of no treatment. Patient-specific healthcare
resource use data were collected and valued using NHS refer-
ence costs, standard unit costs and published literature.20 21
HRQoL was measured and valued using the EQ-5D-3L and UK
social tariff and converted to quality-adjusted life years
(QALYs).22 A random effects model estimated differences in
costs and QALYs for each MAD against control. Bootstrapping
was used to construct cost-effectiveness acceptability curves
(CEACs) and cost-effectiveness acceptability frontier. The
impact of changes in MAD cost, device lifespan and use of
SF6D QALYs on net monetary benefit (NMB) was assessed.
RESULTS
In all, 90 patients were randomised between December 2010
and July 2012 (figure 1). A total of 16 (18%) withdrew from
the trial; 7 (8%) of these did not complete any treatment and
were excluded from analyses. Two additional patients who with-
drew between periods one and two had a failed sleep study but
completed secondary outcomes, making 9 (10%) patients who
provided no AHI data after baseline. Seven patients withdrew
later in the trial. It has been assumed that the data were missing
at random for these patients. There were no differences in base-
line characteristics between those who completed the trial and
those who withdrew, and the pattern of withdrawal did not cor-
respond to any particular MAD (see online supplement). Seven
other sleep studies failed, leaving 305 studies (85% of 360)
from 81 patients (90%) for AHI analysis. For all other out-
comes, 314 (87%) measurements and 83 (92%) patients were
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available for analyses. Baseline characteristics for complete cases
and patients with missing data were similar.
Baseline characteristics for randomised patients are given in
table 1.
Although 12 patients had baseline ESS below 9, they were
eligible based on their ESS being 9 or more at screening.
One patient was erroneously randomised following a screening
ESS of 8 (ESS=10 at baseline). Three patients were randomised
on the basis of more sensitive electroencephalographically-
guided AHI scoring. When later rescored according to rPSG cri-
teria, the AHI was below 5. There were no significant
period-by-treatment interactions and, for AHI and ESS, no
period effects. Complete case results were almost identical to
main analysis of cases with at least one measurement, so only
the latter is reported.
All three MADs significantly decreased the AHI against no
treatment by 26% (95% CI 11% to 38%) for the SP1, 33%
(95% CI 24% to 41%) for the SP2 and 36% (95% CI 24% to
45%) for the bMAD (table 2, figure 2A).
A similar effect was found for all devices against no treatment
for 4% oxygen desaturation index (4% ODI). There were no
significant differences between devices for either AHI or 4%
ODI. Compared with no treatment, patients spent significantly
less time with nocturnal oxygen saturation <90% when using
SP2 and bMAD (SP2 vs no treatment p=0.040 and bMAD vs
no treatment p<0.001, respectively), and there were some
Figure 1 Flow of patients through the trial.
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differences between MADs (bMAD vs SP2, uncorrected for
multiple testing p=0.037; bMAD vs SP1, uncorrected multiple
testing p=0.006). The bMAD had a significant effect on
minimum oxygen saturation compared with no treatment and
the other devices (see online supplement).
Complete response (AHI <5) or partial response (≥50%
reduction in AHI from baseline but AHI ≥5) to treatment was
observed in 17 of 76 (22%) cases after no treatment, and 29/77
(38%), 38/78 (49%) and 33/74 (45%) patients after SP1, SP2
and bMAD, respectively (p=0.0006 for all vs no treatment; see
online supplement). Response was significantly associated with
baseline BMI (OR 0.89/kg/m2, 95% CI 0.80 to 0.98, p=0.014)
and contemporaneous BMI (OR 0.88/kg/m2, 95% CI 0.80 to
0·96, p=0·007). There was a weak association with protrusion
(OR 1.03 per % maximal protrusion, 95% CI 1.00 to 1.05,
p=0.034), although there was no association between % protru-
sion and AHI as a continuous variable (HR 0.997 (0.991 to
1.001), p=0.206). Baseline AHI, ESS, gender, age and compli-
ance were not associated with treatment response.
Median (quartiles) number of nights (of 28) that SP1, SP2
and bMAD were used was 25 (17, 28), 27 (23, 28) and 26 (23,
28), respectively. Mean (SD) nightly use of each device was 4.4
(2.4), 5.7 (2.0) and 5.7 (2.0) hours, respectively (p<0.001 for
both SP2 and bMAD vs SP1). Patients stopped treatment early
during 14 of 81 (17%) SP1, four of 78 (5%) SP2 and six of 76
(8%) bMAD periods (p=0.034).
All MADs decreased ESS significantly compared with no
treatment, by 1.51 units (95% CI 0.73 to 2.29) for the SP1,
2.15 units (95% CI 1.31 to 2.99) for the SP2 and 2.37 units
(95% CI 1.53 to 3.22) for the bMAD (table 2, figure 2B). Based
on Bonferroni corrected comparisons, there were no significant
differences between devices.
Compared with the no treatment arm, total FOSQ score was
significantly higher (better) by 0.50 (95% CI 0.08 to 0.92,
p=0.018) for SP1, 1.10 (95% CI 0.65 to 1.55, p<0.001) for
SP2 and 1.31 (95% CI 0.84 to 1.78, p<0.001) for bMAD.
Total SAQLI score was improved in a similar pattern compared
with no treatment: 0.27 (95% CI 0.07 to 0.48, p=0.008) for
the SP1, 0.62 (95% CI 0.38 to 0.86, p<0.001) for the SP2
and 0.65 (95% CI 0.41 to 0.90, p<0.001) for the bMAD. The
SP2 and bMAD FOSQ and SAQLI scores were significantly
higher (better) than the SP1 (uncorrected p≤0.01). While most
of the SF36 dimensions did not show differences between
MADs, there were important differences in the Vitality Scores
for SP2 and bMAD against no treatment (see online
supplement).
Table 1 Baseline characteristics
Unit/category Total (N=90) Min Max
Demographic information
Gender
Male 72 (80%)
Female 18 (20%)
Age at randomisation
Years 50.9 (11.6) 26.1 79.6
BMI
Kg/m2 30.6 (27.9–35.1) 23.9 54.5
Smoking history
Non-smoker 44 (49%)
Ex-smoker 39 (43%)
Smoker 7 (8%)
Clinical history
Previous CPAP 4 (4%)
Asthma 14 (16%)
Diabetes
Type I 1 (1%)
Type II 7 (8%)
Cardiovascular disease
Previous stroke 2 (2%)
Previous TIA 1 (1%)
Ischaemic heart disease 5 (6%)
Hypertension 23 (26%)
Sleep study
Apnoea-Hypopnoea Index
Events per hour 13.8 (6.2) 2.9 27.7
Missing* 1
Oxygen Desaturation Index
Events per hour 9.8 (5.2) 0.6 22
Minimum SpO2
Per cent 83.7 (4.7) 71 91
Missing* 2
Mean SpO2
Per cent 94.2 (1.3) 89.8 97.7
Missing* 1
Time <90% of nocturnal SpO2
Minutes 8.3 (2.9–24.8) 0 315.4
Missing* 1
Epworth Sleepiness Scale (ESS)
ESS
Unit score 11.9 (3.5) 3 20
Categorical variables show frequency (%) and continuous variables show either mean
(SD) or median (IQR).
*One sleep study failed and inclusion was based on the Desaturation Index.
BMI, body mass index; TIA, Transient Ischaemic Attack.
Figure 2 (A) Mean Apnoea-Hypopnoea Index (AHI) and (B) mean
Epworth Sleepiness Scale (ESS) score (with 95% CIs for each treatment)
from the Poisson mixed effects model.
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Mean (SD) mandibular protrusion for the SP1 was greater
than for the other two devices (SP1, 62.6% (22.1); SP2, 51.7%
(26.4), uncorrected p<0.001; bMAD, 55.2% (19.7), uncor-
rected p=0.012). Patients found the SP1 less comfortable and
were less satisfied with it than the SP2 and bMAD (see online
supplement). The SP1 was more likely to fall out or be
removed.
Of 74 trial completers, 30 (41%) ranked the bMAD highest
in terms of preference and 23 (31%) ranked it second (see
online supplement). SP2 was ranked highest by 22 (30%) and
second by 34 (46%) patients, while 10 (14%) favoured no treat-
ment. After the trial, 56 of 74 (76%) completers continued
treatment with their preferred MAD and 4 (5%) others chose
treatment with the MAD that achieved the best AHI.
There were four serious adverse events during the trial.
Minor adverse events were experienced by 86 (96%) patients.
Most common were mouth problems/discomfort (83, 92%) and
excess salivation (48, 53%) with SP2 performing best for both
(see online supplement).
All devices were cost-effective compared with no treatment at
a willingness-to-pay (WTP) of £20 000/QALY, based on mean
costs and QALYs. SP2 achieved the highest NMB at £33 per
4 weeks (table 3).
On average, the SP1 and SP2 point estimates were associated
with more QALYs and lower mean costs compared with no
treatment, although QALY differences between devices were
small and non-significant. These results are robust to: changes in
a device’s price and lifespan; increasing the WTP per QALY to
£30 000; and using only complete case analysis. When the
bMAD price exceeds £525 or average lifespan falls below
14 months, it no longer has a positive NMB. The CEAC
(figure 3A) and NMB (figure 3B) show SP2 to be most cost-
effective up to a WTP of £39 800/ QALY, at which point bMAD
supersedes it (39% likelihood of being cost-effective vs 35% for
the SP2). Below a WTP of £5000/QALY, only SP2 is more cost-
effective than no treatment. The finding that SP2 was the most
cost-effective option was strengthened considerably when using
SF6D QALYs.
DISCUSSION
This trial showed that in mild to moderate OSAHS, non-
adjustable MADs improve objective and subjective health
outcomes over no treatment. Additional improvements dimin-
ished with increasing MAD sophistication but the consistent
results across outcomes suggest genuine effects. All devices were
cost-effective against no treatment based on the point estimates
of costs and QALYs. However, differences in EQ-5D-3L results
between devices were small and non-significant, although signifi-
cant using SF6D QALYs. Probabilistic analysis, accounting for
uncertainty in costs and QALYs, showed SP2 was the most cost-
effective up to a WTP of £39 800/QALY. Above this WTP,
bMAD appeared most cost-effective in the short term, although
not using SF6D QALYs.
All MADs reduced AHI to between 64% and 75% of no
treatment AHI, which is modest. Pneumatic splinting of CPAP
efficiently controls multilevel pharyngeal collapse. The mechan-
isms of action of MADs are more complex, probably involving
airway stiffening, splinting and enlargement.23 These factors
and level of obstruction vary between patients, impacting MAD
efficacy. Greater AHI effects have been reported24 25 but meth-
odological and device heterogeneity complicate interpretation
of the comparisons. Many studies also include patients with
more severe disease at baseline,24 26 which gives more potential
for useful treatments to show an effect. The focus of the trial of
oral mandibular advancement devices for obstructive sleep
apnoea-hypopnoea (TOMADO) was on milder disease, where a
no treatment control was particularly relevant. The RCT most
comparable with TOMADO, which used a maximally titrated
adjustable MAD in mild to moderate OSAHS, reported a mean
AHI of 67% against placebo tablet, which is consistent with our
results.9
Reduction of AHI can be proportional to mandibular protru-
sion.27 Mean (SD) protrusion in this trial (4.8 (2.5) (SP2) to 5.7
(2.1) (SP1) mm (52.5 (27.8)% to 63.4 (22.6)% maximal
advancement)) was lower than others have achieved,18 28 often
using adjustable MADs.9 17 24 26 29 However, greater protrusion
in those trials did not always achieve greater AHI reduction
than TOMADO.9 18 The results from this trial did not demon-
strate a convincing association between protrusion and AHI.
There is also evidence that maximal protrusion may not be
necessary in milder OSAHS.30
All MADs studied were associated with a statistically signifi-
cant improvement in ESS. The SP1 improvement was of border-
line clinical significance compared with no treatment. The ESS
Table 2 Summary of results from mixed effects models for AHI (n=81) and ESS (n=83)
Mean (SD) Coefficient 95% CI p Value Global p value
AHI (n=81)
Constant 14.22 (11.66 to 17.34) <0.001
Relative AHI compared with no treatment
No treatment 14.6 (10.5) – – – <0.001
SP1 10.8 (9.5) 0.74 (0.62 to 0.89) 0.001
SP2 9.7 (8.9) 0.67 (0.59 to 0.76) <0.001
bMAD 9.5 (8.4) 0.64 (0.55 to 0.76) <0.001
ESS (n=83)
Constant 10.65 (9.64 to 11.66) <0.001
Difference in ESS compared with no treatment
No treatment 10.1 (4.3) – – – <0.001
SP1 8.5 (4.0) −1.51 (−2.29 to −0.73) <0.001
SP2 8.0 (4.1) −2.15 (−2.99 to −1.31) <0.001
bMAD 7.7 (3.8) −2.37 (−3.22 to −1.53) <0.001
AHI, Apnoea-Hypopnoea Index; bMAD, bespoke mandibular advancement device; ESS, Epworth Sleepiness Scale.
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effects for the SP2 and bMAD were greater and similar to some
of those reported for CPAP in OSAHS.17 Placebo effects cannot
be ignored. A recent study attributed up to 29% of ESS
response to expectation of benefit from high CPAP compli-
ance;31 but the associated objective AHI reductions in this study
suggest real effects.
Patient-reported MAD compliance was good, and the reliabil-
ity of subjective measurement has been objectively demon-
strated.32 Compliance was lower for SP1, which was less well
tolerated and often fell out or was removed. Poor retention of a
non-bMAD has been related to inferior compliance,25 while
superior MAD compliance is considered key to matching CPAP
health outcomes.17 The SP1’s unpopularity at trial exit and
poorer in-trial compliance suggest there are significant obstacles
to its longer term effectiveness.
This relatively large study used an efficient design to estimate
the short-term effectiveness of MADs on the most relevant out-
comes in OSAHS: AHI and EDS. The results were clear, unam-
biguously significant and robust to assumptions for incomplete
data. Seven patients failed to complete any treatment and two
dropped out after one period. We therefore estimate that 10% of
patients eligible for a MAD will prove intolerant. Another 8%
may become intolerant later. This highlights the need for longer
term data regarding MAD usage. Current ongoing follow-up of
trial patients will eventually assess longer term device durability
and compliance but until this information becomes available,
modelling of long-term outcomes must be relied upon.
This study was conducted at a specialist centre, potentially
limiting generalisability. However, participants were recruited
from our usual clinic population, mostly referred from primary
care. The SP1 and SP2 are available in many countries and
similar to other thermoplastic and ‘semi-bespoke’ MADs. The
bMAD was similar in design to other available monobloc
devices. It was fitted and manufactured by a hospital maxillo-
facial laboratory, but using skills, materials and facilities
common to dental sleep services.
Although the aim for the bMAD was at least 50% maximal
protrusion, this was often lower and similar to that achieved
independently by patients with the other devices. This reflects
the pragmatic nature of the trial, making its findings more
applicable to the wider NHS. Including an adjustable MAD may
have achieved greater protrusion and would have extended this
effectiveness evaluation. However, the need to adequately cover
the range of non-adjustable MADs available to NHS sleep ser-
vices precluded this. Although they are more costly, adjustable
MADs are increasingly recommended.33 34 Titration is thought
to optimise protrusion and tolerance35 but their superiority
remains unproven. A large retrospective review of mild to
severe OSAHS patients fitted with a bMAD reported slightly
greater AHI effects for an adjustable MAD compared with a
non-adjustable device. However, differences were often not stat-
istically significant and clinical significance was doubtful given
that ESS reductions were no different.34 The inconsistent evi-
dence regarding greater protrusion in milder disease has already
been discussed, and the high reported compliance with our
bespoke devices leaves little room for improvement.
Nonetheless, the increasing popularity of more expensive adjust-
able MADs means rigorous prospective comparisons should be
a priority.
In the short term, MADs achieve clinically significant
improvements in mild to moderate OSAHS and appear cost-
effective at £20 000/QALY compared with no treatment.
Inferior tolerance and retention of the SP1 device may limit its
effectiveness. Minor differences between the two more sophisti-
cated devices suggest that a semi-bespoke non-adjustable MAD
could be a practical and efficient first choice in most patients. A
Table 3 Comparison of costs and QALYs from devices against control
Intervention
Cost component (£)
No treatment
n=78
SP1
n=81
SP2
n=78
bMAD
n=77
Device (fixed) – £21 £128 £350
Measurement for device (fixed) – – – £110.37
Fitting of device (fixed) – – – £92.04
Additional visit if required (average across all patients) – – – £5.98
Subtotal – £21 £128 £350
Device lifespan (months) (fixed) – 12 12 18
Cost of intervention subtotal pro rata (4 weeks) (fixed)* – £1.62 £9.85 £28.64
Summary of costs (£) Mean SE Mean SE Mean SE Mean SE
Resource use cost (4 weeks) Mean (SD)† £78.50 £19.97 £73.02 £10.47 £53.58 £8.05 £76.25 £24.40
Total cost (4 weeks) Mean (SD)† £78.50 £19.97 £74.64 £10.47 £63.43 £8.05 £104.89 £24.39
Total cost difference intervention vs control – – −£3.87 £21.38 −£15.08 £20.62 £26.39 £27.94
Health-related quality of life measure
EQ-5D-3L Utility score 0.85 0.2 0.86 0.2 0.86 0.23 0.87 0.19
EQ-5D-3L QALY score (4-week trial period)‡ 0.0649 0.0017 0.0658 0.0017 0.0658 0.0019 0.0667 0.0017
QALY score difference intervention vs control – – 0.00094 0.00105 0.00088 0.00123 0.00177 0.00147
Cost effectiveness measure
Incremental Cost-Effectiveness Ratio – −£4093 −£17 104 £14 876
Net monetary benefit (willingness-to-pay=£20 000) – £23 £33 £9
*Device and fitting costs are pro rata to be comparable over the 4-week trial period.
†Resource use and total costs by intervention estimated using a mixed effects model controlling for baseline data. All costs in 2011/2012 (£).
‡QALY scores calculated using area under the curve method to represent the true QALY score for the 4-week intervention period and to be consistent with the costs presented.
bMAD, bespoke mandibular advancement device; QALY, quality-adjusted life year.
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bespoke device may be necessary for those patients who require
dental help with production and fitting of a MAD, or where
there are concerns regarding dental eligibility and oral health,
and this approach should be considered for inclusion in clinical
guidelines. However, longer term compliance and the potential
impact of unknown differences in device durability are being
explored in a longer term evaluation of this cohort to help
determine whether minor differences between patient-fitted and
dentally-produced MADs are important. In addition, the effects
on cardiovascular events and road traffic accidents are being
studied in a long-term cost-effectiveness model. Finally, whether
adjustable devices are cost-effective and offer clinically signifi-
cant advantages over bespoke non-adjustable devices in the real
life setting still need to be explored.
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